Zydus Cadila COVID-19 Vaccine for kids: The Centre stated in an affidavit addressed to the Delhi High Court dated July 15 that the ZyCoV-D vaccine can be available soon for children aged 12 years to 18 years.
Under Secretary to the Ministry of Health and Family Welfare Satyendra Singh said, “It is submitted that Zydus Cadila which is developing a DNA vaccine has successfully concluded its clinical trial for the 12-18 age group,” in the affidavit.
Through the concerned affidavit, the Centre was responding to a plea filed by Tia Gupta, a minor who had sought immediate vaccines for children aged between 12 and 17 years. The court however noted, “Administration Of Covid-19 Vaccines To Children Without Proper Research Will Be A Disaster.”
— Live Law (@LiveLawIndia) July 16, 2021
Ahmedabad-based Zydus Cadila stated on July 1 that they were planning to roll out the ZyCoV-D vaccine within 45-60 days, subject to the Drug Controller General of India’s (DCGI) go-ahead.
The manufacturers added that at the beginning, they will be able to produce four to five lakh doses a month. Eventually, the number of doses will rise to one crore per month which will be after their new manufacturing facility becomes operational from July-end.
Meanwhile, Dr VK Paul, Member-Health, Niti Aayog on being asked when Zydus Cadila’s COVID vaccine for children will be available said, “DCGI is examining it. More data is needed. The scientific process has to be completed. We have to be lucky that it should be effective and safe.'”
DCGI is examining it. More data is needed. The scientific process has to be completed. We have to be lucky that it should be effective and safe: Dr VK Paul, Member (Health), Niti Aayog on being asked 'when Zydus Cadila's COVID vaccine for children will be available' pic.twitter.com/y0PL96nZ5A
— ANI (@ANI) July 16, 2021
Here Is What You Need To Know About The Zydus Cadila COVID Vaccine
- This is claimed to be the first needle-free DNA plasmid-based COVID-19 vaccine.
- Being a needle-free injector-administered intradermal vaccination, there should be a considerable reduction in side effects the pharma giant has claimed.
- ZyCoV-D will be a three-dose vaccine.
- The vaccine can be stored at two to four degrees Celsius and does not require refrigeration, resulting in easier transportation to even the most remote corners of the country.
- The vaccine has a 66.6 per cent efficacy against symptomatic patients of coronavirus while a 100 per cent efficacy against moderate disease symptoms.
- According to reports, Zydus Cadila has undertaken the largest COVID-19 vaccination clinical trial in India, with over 50 centres.